retatrutide 1.5 mg a week Research Concentration Overview Retatrutide Promises Big Weight Loss,
Description
Weight regain is commonly observed after stopping GLP-1 therapy
GIP-overexpressing mice demonstrate reduced diet-induced obesity and steatosis, and improved glucose homeostasis
This mechanism is distinct from currently approved medications such as semaglutide and tirzepatide, which act as dual agonists
Sexton for valuable interactions
Already reported (and cleared primary endpoints): TRIUMPH-1 pivotal general obesity (May 21, 2026) 28.3% weight loss at 80 weeks, 30.3% at 104 weeks in a pre-specified extension
